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 Abstract 
Background & Aims:  Minocycline hepatotoxicity can present with prominent autoimmune features in 
previously healthy individuals. The aim of this study was to identify genetic determinants of minocycline 
DILI in a well-phenotyped cohort of patients. Methods:  Caucasian patients with minocycline DILI 
underwent genome-wide genotyping and were compared to unexposed population controls. Human 
leukocyte antigen (HLA) binding of minocycline was assessed using AutoDock Vina. Results:   Amongst 
the 25 cases, 80% were female, median age was 19 years and median latency from drug start to DILI 
onset was 318 days.  At presentation, 76% had acute hepatocellular liver injury, median ALT 1077 U/L 
(range: 63 to 2333), median bilirubin 4.5 mg/dl (range: 0.2 to 16.7), and 90% had a +ANA. During follow-
up, 50% were treated with corticosteroids and no subjects died or required a liver transplant. A 
significant association was noted between HLA-B*35:02 and risk for minocycline-DILI;  a 16% carrier 
frequency in DILI cases compared to 0.6% in population controls (Odds Ratio: 29.6, 95% CI: 7.8-89.8, 
p=2.5 x 10
-8
). Verification of HLA-B*35:02 imputation was confirmed by sequence-based HLA typing.  
HLA-B*35:02 carriers had similar presenting features and outcomes compared to non-carriers. In silico 
modeling studies support the hypothesis that direct binding of minocycline to this novel HLA risk allele 
might be an important initiating event in minocycline-DILI. Conclusion:  HLA-B*35:02 is a rare HLA allele 
that was more frequently identified in the 25 minocycline-DILI cases compared to population controls. If 
confirmed in other cohorts, this HLA allele may prove to be a useful diagnostic marker of minocycline 
DILI.  
 
Words:  252 
 
Lay summary:   Development of liver injury following prolonged use of minocycline for acne is a rare but 
potentially severe form of drug induced liver injury.  Our study demonstrates that individuals who are 
HLA-B *35:02 carriers are at increased risk of developing minocycline related liver injury.  These results 
may help doctors more rapidly and confidently diagnose affected patients and possibly reduce the risk 
of liver injury in individuals receiving minocycline going forward.  
 
Graphical abstract:  See attached PDF 
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Idiosyncratic drug induced liver injury (DILI) is an important cause of acute and chronic liver injury in 
western patients.  In addition to being a leading reason for regulatory actions amongst drugs in 
development and in the marketplace, DILI also accounts for 13% of adults with acute liver failure (1).  A 
recent population based study indicated that the annual incidence of DILI was 19.1 per 100,000 person 
years in Iceland and that antibiotics were the most commonly implicated agents (2). Similarly, analyses 
from the ongoing Drug induced Liver Injury Network (DILIN) prospective study in the United States also 
identified antibiotics as the leading cause of DILI, with amoxicillin-clavulanate being most frequently 
implicated (3).   Prior reports have also implicated minocycline as a cause of DILI with characteristic 
clinical features including systemic arthralgias and detectable autoantibodies arising in young women 
(4).    Recent studies have suggested that various laboratory, histological and clinical features can help 
differentiate auto-immune like DILI from sporadic autoimmune hepatitis but confirmatory studies are 
needed (4).   
Several groups have begun studies to better define the presenting features, risk factors, and outcomes 
of patients with DILI. In addition to identifying improved causality assessment methods and DILI 
biomarkers, studies exploring the potential genetic susceptibility in these rare patients with DILI have 
been undertaken.  Prior genome wide association studies (GWAS) have identified single nucleotide 
polymorphisms in the Human Leukocyte Antigen (HLA) locus that are associated with DILI susceptibility 
to several drugs (5-8).   The aim of the current study is to report upon the presenting clinical features 
and outcomes of patients with DILI attributed to minocycline that have enrolled into the ongoing DILIN 
prospective and retrospective studies.  In addition to exploring clinical phenotypes, we also set out to 
identify potential genetic susceptibility factors in patients with minocycline DILI compared to population 
controls, using GWAS and confirmatory sequence-based HLA typing. Finally, preliminary results 
exploring the potential mechanism of the HLA-B*35:02 association with minocycline DILI using in silico 
modelling are presented. 
Methods 
DILIN Prospective study-   Most of the subjects were enrolled in the DILIN prospective study protocol. 
DILI onset was defined as the first date after a subject taking minocycline met the predefined 
laboratory criteria for study entry, of either a serum aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) level that exceeded 5 x the upper limit of normal (ULN) (or 5 X 
pretreatment baseline if baseline abnormal), a serum alkaline phosphatase (Alk P) that 
exceeded 2 X the ULN (or 2 X pretreatment baseline if baseline abnormal), a total bilirubin > 2.5 
mg/dl, or an international normalized ratio (INR) greater than 1.5 on two consecutive blood 
draws.  All study participants were enrolled within 6 months of DILI onset.   
A detailed medical history was obtained at the baseline study visit and additional laboratory 
and radiological testing were performed to more fully characterize the DILI event and exclude 
competing etiologies.  Specifically, testing for hepatitis A, B, C, HIV, autoantibodies including 
anti-nuclear antibody titers, CMV, and EBV infection were obtained at the local laboratory.   
Enrolled patients were seen for a follow-up study visit at 6 months after initial enrollment and 
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those with evidence of chronic DILI within 6 months of DILI onset were asked to return for 
additional follow-up visits at 12 and 24 months (9).   Chronic DILI was defined as having a 
persistently elevated serum AST, ALT, or alk phos level, histological evidence of liver injury, or clinical 
evidence of portal hypertension at 6 months after DILI onset.   Written informed consent was obtained 
from subjects and the study was approved by the Institutional Review Boards of all participating clinical 
sites.    
The severity of the DILI episode was categorized on a 5-point scale from mild (1), moderate (2), 
moderate-hospitalized (3), severe (4), and fatal (5), where a fatal score was assigned only if the 
patient died or had liver transplant due to DILI (9).   Of note, the clinical features of some of the 
minocycline patients were previously presented in a separate report (10). In addition, clinical 
features from 2 of these cases have been posted as brief vignettes on the LiverTox website (see 
http://livertox.nlm.nih.gov/minocycline).  
DILIN Retrospective study-  DNA samples and phenotypic data from subjects with minocycline 
hepatotoxicity enrolled in the DILIN retrospective study were included.   Study inclusion criteria were 
patients that developed DILI due to one of 8 prespecified drugs that included minocycline with a DILI 
onset date after 1994.  Subjects had to have a total bilirubin of > 2.5 mg/dl and a complete set of labs at 
DILI onset, exclusion of competing causes, and outcome available for review.   Retrospective study 
patients were either interviewed in person or over the phone to review the dose and duration of 
suspect medication use and facilitate collection of a DNA sample after obtaining written informed 
consent.    
DILIGEN study-  Only Caucasian subjects with DILI attributed to minocycline enrolled in the DILIGEN 
study with an available DNA sample were included.  All subjects had (a) clinically apparent jaundice or 
bilirubin > 40 umol/L, or (b) a serum ALT > 5 X ULN or (c) Alk P > 2 X ULN plus any raised bilirubin above 
ULN (7). All patients had a Roussel Uclaf Causality Assessment Method (RUCAM) causality score of 3 
or greater. 
Liver histopathology-  Available liver biopsies were reviewed by a single expert liver histopathologist 
(DEK).  All samples were scored for multiple histological features as well as an overall pattern of liver 
injury (11).   
Causality assessment-   The causal relationship between the liver injury episode and the 
minocycline use were evaluated in a standardized fashion by the DILIN causality committee 
(12).   A DILIN expert opinion causality score varying from 1 (Definite > 95% likelihood), 2 
(Highly Likely 75%-95% likelihood), 3 (Probable 50%-74% likelihood), 4 (Possible 25%-49% 
likelihood) to 5 (unlikely < 25% likelihood) was assigned by consensus agreement of committee 
members for all of the retrospective and prospective DILIN cases.  In addition, a RUCAM score 
was calculated for each case and implicated agent (13).   In subjects with 2 or more implicated 
drugs, an overall causality score was assigned to the case and then an individual causality score 
for each drug was given.    
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Controls  
Since DILI has a very low prevalence and minocycline is widely prescribed in healthy individuals 
with an estimated 4.2 million prescriptions of tetracylines per year in the US, unselected 
population samples were used as study controls (14).  We selected 10,588 Caucasian controls 
from different available sources; the Welcome Trust Case Control Consortium (WTCCC) 
(http://www.wtccc.org.uk), the population reference sample (POPRES)and PGX4000118 and 
Spanish Bladder cancer cohort from dbGAP (phs000346.v1).  Since all cases of minocycline DILI 
were determined to be of primarily Northern European ancestry, the set of ancestry-matched 
controls totaled 6,835 individuals.  Since prior medication exposure history was not available 
for the controls, we presume that none of these patients previously received minocycline.    
Genome-wide SNP and HLA analysis 
Genome-wide genotyping of DILI cases was performed by the Broad Institute in Boston by 
Illumina Infinium HumanCoreExome BeadChip (n=19) or at the Duke Center for Human Genome 
Variation on the Illumina 1Mduo array (n=6).  A total of 505,740 markers shared across the 
different genotyping platforms used for DILI cases and controls passed quality control (QC) and 
no samples were excluded for low quality profile.  
For each cohort, single nucleotide polymorphisms (SNPs) with poor quality data were pruned 
before the imputation to avoid false positives. The imputation was performed by batches 
dividing the cohorts by the genotyping platform used. For each batch, we first phased the data 
by SHAPEIT (version v2.r727)(15), to increase the accuracy of the imputation. Then, imputation 
was carried out using IMPUTE2 (version 3) with the 1000 Genomes Project (release v321) 
dataset as the reference panel (16). We used an ethnically mixed panel to improve the quality 
of the imputation for rare variants. We retained imputed genotypes with: (a) posterior 
probability > 0.9  in each genotyping batch, (b) no significant difference in missingness between 
cases and controls (χ2 test, p-value > 0.0001), (c) no significant deviation from Hardy-Weinberg 
equilibrium (p-value > 0.0001), (d) missing data not greater than 5% in each single genotyping 
batch, (e) info score greater than 0.8 in each genotyping batch. Since the imputation quality is 
higher for common variants, we selected SNPs with MAF in the 1000 Genomes Project greater 
or equal of 0.01. The imputed cohorts were then merged and genotyped SNPs were used to 
replace imputed SNP genotypes if previously eliminated during the build of the batch groups. 
For each imputed SNP, possible batch effects were detected by testing the association (by 
logistic regression) between controls within the same population typed by different platforms. 
SNPs with association p-values less than 0.005 in this control comparison were excluded from 
the analysis. For each cohort, HLA alleles were also inferred using HIBAG (17) using the 
reference predictor panels specific for each genotyped chip. The top associated HLA type was 
further validated by sequence-based HLA typing at Histogenetics (Ossining, NY, USA).  A proxy 
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for HLA-B*35:02, rs148631562, was typed with a TaqMan® SNP genotyping assay (ThermoFisher 
Scientific, Waltham, MA) in accordance with the manufacturer's recommendations in 7 
additional European ethnicity cases. 
Statistical analysis 
The effect of population structure was assessed through principal components analysis (PCA) 
using the smartPCA program from the EIGENSTRAT package (version 3.0) (18). The statistical 
association of each marker (HLA allele or SNP) with risk for minocycline DILI was determined by 
logistic regression with the first ten significant principal components as covariates under an 
additive genetic model. The lack of association between the HLA-B*35:02 allele and 
EIGENSTRAT axes can be seen in Figure S1.  Association and heterogeneity tests were carried 
out using PLINK (19). We set the genome-wide significance p-value threshold to 1.0 x 10
-8
 to 
correct for multiple testing.  Given the high prior probability of HLA association with risk for 
DILI, an HLA-wide significance threshold was determined by Bonferroni correction for the 217 
HLA alleles tested for association (p=2.3 X 10
-4
). No test statistic inflation was observed for the 
results (Figures S2 and S3). To test for independent effects within regions having multiple 
associated variants, we included one or more variants as covariates and tested the residual 
effect of these variants after adjusting for the top associated allele.  Differences in clinical 
characteristics among sample groups were tested by Fisher's Exact test or one-way ANOVA. All 
detailed analyses and Manhattan plots were performed with R (Version 3.0.2). Regional plots 
were drawn by LocusZoom (20). 
HLA modelling and molecular docking 
An atomic model of HLA-B*35:02 was generated by SWISS-MODEL (21) using the HLA-B*35:02 
sequence found in IMGT/HLA (22). The SMILES string of minocycline was obtained from 
PubChem and translated into 3 dimensional coordinates using the NCI/CADD translator 
(http://cactus.nci.nih.gov/translate/). AutoDock Tools was used to prepare files for molecular 
docking using AutoDock Vina (23). The top 9 scoring orientations were studied with the highest 
scoring pose shown in Figure 3. 
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RESULTS 
Patient population-  A total of 25 Caucasian patients with DILI attributed to minocycline constitute our 
study population.   Eighteen of the patients were enrolled in the DILIN prospective study, 4 were 
recruited in the DILIN retrospective study and 3 subjects were enrolled from DILIGEN.   As shown in 
Table 1, the majority of subjects were female (80%) with a median age of 19 years (range: 16-61).  
Indications for minocycline use were dermatologic in 100%.   At presentation, the majority of subjects 
had an acute hepatocellular pattern of liver injury with a median serum ALT of 1077 U/L, median Alk P of 
176 U/L, and 52% of the subjects were jaundiced.  The median duration of minocycline use was 55 
weeks (range:   < 1 to >122) with 52% having taken the drug for > 12 months. Hypersensitivity features 
at presentation included 4% with eosinophilia, 32% with fever, and 20% with a rash.  The majority of 
subjects had a + ANA (90%) determined at their local hospital lab, 32% had detectable smooth muscle 
antibody, and 58% had hypergammaglobulinemia. 
A liver biopsy was obtained during the process of clinical evaluation and available for central review in 8 
subjects (Table 2).   The time from DILI onset to liver biopsy varied from 2 to 220 days with a median 
time of 73 days.  The pattern of injury was acute (lobular predominant) hepatitis in 3 patients and 
chronic (portal predominant) hepatitis in 5 patients.  In 2 of the cases of acute hepatitis and one of the 
cases of chronic hepatitis, there was mild to moderate zone 3 bile accumulation (cholestatic hepatitis).  
Half of the cases had marked interface hepatitis and in 2 cases, this was associated with bridging 
necrosis.  Mild confluent necrosis was seen in 3 cases.  Portal plasma cell infiltrates were prominent in 3 
cases, while eosinophils were prominent in 5 cases.  The 3 cases of cholestatic hepatitis all had 
prominent portal neutrophil infiltrates.  On the basis of pattern and plasma cell infiltration only 3 cases 
showed classic features that would suggest autoimmune hepatitis.  Fibrosis was present as periportal 
expansion in most cases, but two cases had evidence of early bridging fibrosis. 
During follow-up, none of the patients died or underwent liver transplantation.   However, 5 (28%) of 
the 18 DILIN prospective patients met pre-determined criteria for chronic DILI at 6 months after injury 
onset.  At 24 months of follow-up, all 5 patients had normalized their labs.   Local physicians treated 12 
subjects (50%) with corticosteroids.  The median duration of steroid use was 160 days (range:  4 to 435 
days) and 27% of the DILIN patients remained on steroids for at least 6 months after DILI onset.   
Genetic association studies-   A genome-wide association study was undertaken on the 25 minocycline 
DILI cases, including association testing of HLA alleles imputed from SNP genotype data in the major 
histocompatibility complex (MHC) region on chromosome 6.   The results of the genome-wide scan did 
not reveal any individual SNP or genomic region showing significant association with risk for 
minocycline-DILI after multiple test correction. However, when assessing the HLA types imputed from 
SNP genotype data in the MHC region, we observed a significant enrichment of the HLA-B*35:02 allele in 
the cases versus population controls (16% vs 0.6%, Odds ratio 29.6, 95% CI:  7.8-89.8, p = 2.5 X 10-
8
) 
(Table 3). The association with the imputed HLA-B*35:02 allele was then confirmed with sequence-
based HLA typing (Figures 1 and 2).  
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HLA docking studies-   Although the mechanistic basis for HLA associations with DILI is not known, it is 
presumed to involve: 1) direct binding of either the drug or a drug metabolite to HLA molecules or a 
metabolite-peptide adduct binding to HLA molecules, 2) effects on selection (expansion or deletion) of 
HLA restricted drug-specific T cells, and/or 3) indirect effects due to linked causative genes. To 
determine if minocycline has the potential to bind HLA-B*35:02, we used molecular docking to predict 
putative interactions. Although the structure of HLA-B*35:02 has not been solved, it is sufficiently 
similar (98.9 %) to a solved crystal structure (HLA-B*35:01, PDB code 1XH3) allowing the generation of a 
high confidence model. The crystal structure of abacavir bound to HLA-B*57:01 provided a rational basis 
for prediction of sites within the antigen binding cleft that permit drug/HLA interactions (24, 25) . We 
used a high confidence model of HLA-B*35:02 and knowledge of drug/HLA contact sites to predict the 
likelihood of direct minocycline interactions with HLA-B*35:02.   We used AutoDock Vina to dock 
minocycline into the antigen binding cleft of HLA-B*35:02 yielding a predicted interaction (estimated 
ΔG=-7.9 kcal per mole, compared to control docking of abacavir into HLA-B*57:01, ΔG=-7.2 kcal per 
mole (Figure 3). These data suggest that minocycline has the potential to bind the HLA-B*35:02 antigen 
binding cleft.  
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Discussion 
Our study demonstrates a higher frequency of HLA-B*35:02 amongst the 25 patients with minocycline 
DILI compared to a large group of population controls.  The GWAS results were confirmed using 
sequence-based HLA typing.   Although further validation in an independent and larger group of patients 
with minocycline DILI are needed, the results are in line with previous genetic studies of DILI showing 
(often drug-specific) risk factors in both HLA Class I and HLA Class II genes (5,6).  HLA-B*35:02 has a low 
frequency in the general population, with an allele frequency of only 0.3% in Caucasians and less than 
0.1% in African Americans. 
A review of the literature demonstrates that HLA-* 35:02 is moderately associated with the rate of HIV 
progression to AIDS in Caucasian patients (26).   It remains possible that HLA*B-35:02 could be a marker 
for the underlying condition of facial acne for which minocycline was prescribed.  However, prior GWAS 
in patients with acne has failed to demonstrate this association (27-29).   Furthermore, our molecular 
docking data suggest that minocycline is capable of binding within the HLA-B*35:02 antigen binding 
cleft, and may potentially alter the profile of peptides that normally bind to HLA-B*35:02, as has been 
shown with abacavir binding to HLA-B*57:01 (30).   Crystal structures demonstrate that abacavir forms 
contact with specific peptides and HLA-B*57:01. Several contacts between the drug, peptide and HLA 
are mediated by ordered water molecules. Molecular docking of minocycline to HLA-B*35:02 is limited 
by lack of knowledge regarding peptides that bind in the presence of the drug. Moreover, it is not 
possible to accurately predict the locations of ordered water molecules in a model of HLA-B*35:02. 
Future studies characterizing peptides bound to HLA-B*35:02 are expected to elucidate functional drug 
interaction mechanisms for this (and other) HLA-DILI associations.    
No significant difference in clinical presentation or outcome based upon HLA-B* 35:02 genotype was 
observed except for lower total bilirubin levels and R-values (Table 1) (see supplemental Table 1 for 
additional information).  This may be due to the limited number of cases enrolled (25), with only 4 HLA-
B*35:02 carriers among this set, or a true lack of difference in presentation or outcomes related to HLA-
B*35:02 carrier status.  A larger number of minocycline DILI cases used for genetic validation could also 
help determine if the HLA-B*35:02 carriers have any unique clinical or laboratory features compared to 
non-carriers with minocycline DILI.  Nonetheless, our data are consistent with other GWAS studies in 
DILI subjects demonstrating an association of HLA region with DILI susceptibility (31-33).  Many of these 
are in the HLA Class I genes (specifically, HLA-A or HLA-B), though the HLA Class II genes have also been 
implicated.    These studies suggest a role for adaptive immunity in DILI pathogenesis.     
Many of our patients had autoimmune like features at presentation.  Furthermore, available liver 
biopsies demonstrated some features of AIH in some patients (Table 2).   Up to 50% of patients were 
treated with steroids and most did well.  Steroids were successfully tapered off in most patients.  
Although there were no liver transplants or deaths, 24% evolved into chronic DILI which is higher than 
our prior report (9).  This may in part be due to prolonged use of the drug in these patients.  
Furthermore, most of these patients did not get routine labs drawn prior to use.    Lastly, a substantial 
delay between first evidence of DILI (abnormal labs) and drug cessation was observed with 11 subjects 
discontinuing the drug after a median of 38 days after DILI onset.  Prior studies have suggested that 
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continued suspect drug use is associated with more severe DILI and chronicity (34).   However, the 
median duration of minocycline use in the 5 DILIN subjects who developed chronic DILI was not 
significantly longer than the duration of use in the 12 without chronic DILI (252 vs 400 days, p=0.6). And 
the duration of minocycline use after DILI onset was not longer in those with chronic vs self-limited DILI 
(1 day for both groups, p=0.8).   Fortunately at month 24 of follow-up, none of the 5 chronic DILI 
patients had evidence of cirrhosis, portal hypertension or liver failure and in fact all had normalized their 
liver biochemistries.    
Recent studies have suggested that certain HLA alleles (i.e.  HLA-DRB1*0301, HLA-DRB1*0401) may be 
associated with susceptibility to autoimmune hepatitis in Caucasians (35).   When we looked for these 
specific alleles, there was no over-representation in our minocycline cases compared to population 
controls (Data not shown).   However, the lack of an association may be due to lack of power owing to 
the small number of minocycline DILI cases.  
Given the low incidence of DILI amongst patients receiving minocycline, HLA typing is unlikely to help 
prevent minocycline DILI.  However, HLA-B*35:02 may be useful as a diagnostic aid in the setting of 
suspected minocycline DILI especially in distinguishing it from sporadic autoimmune hepatitis but 
confirmatory studies are needed.  In addition due to the small number of case patients that carry the 
HLA-B*35:02 allele (n=4), validation of these findings in a larger, independent cohort of patients with 
minocycline DILI is needed.   
The mechanism linking minocycline to HLA-B*35:02 is not clear. One possibility is that the drug binds 
directly to the antigen binding cleft similar to abacavir binding to HLA-B*57:01, and alters the repertoire 
of bound 9mer peptide ligands- presumably presenting novel cell surface antigens. However, 
minocycline (molecular weight  493.9 daltons) is larger than abacavir (molecular weight 286.3 daltons) 
and may hinder conventional 9mer peptide ligand interactions. That is, minocycline may be presented in 
the absence of conventional peptides (e.g., 9mers). An alternative model is that minocycline metabolites 
bind HLA, forming complexes recognized by CD8
+
 cytotoxic T-lymphocytes. Another potential 
mechanism is that stressed/damaged hepatocytes exhibit immunogenic peptide/HLA complexes that act 
as neoantigens. It also remains possible that minocycline or a metabolite binds covalently to cellular 
proteins resulting in the presentation of a drug-peptide complex to T-cells via HLA-B* 35:02, as appears 
to occur with flucloxacillin in HLA-B * 57:01 carriers (36).  Evidence for the formation of a reactive 
intermediate(s) from minocycline but not other tetracyclines has been reported previously (37).   Our 
group and others are planning additional in vitro experiments in patients with and without the HLA-B * 
35:02 allele to follow-up on these preliminary studies.   Elucidating the mechanism(s) underlying the 
association between HLA-B*35:02 and risk for minocycline hepatotoxicity will lead to a greater 
understanding of the pathophysiology of liver injury from minocycline, and perhaps other hepatotoxic 
drugs. 
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Figure legends 
Figure 1.  Manhattan plot showing genome-wide single variant association test results. The  -log10(P 
value) from a logistic regression of each SNP on phenotype is plotted according to physical location  of 
the SNPs on each of the 22 autosomes, with SNPs on different chromosomes colored with alternating 
colors. SNPs that exceeded a  p-value of 10
-5
 threshold are marked in green color. 
Figure 2.  LocusZoom plot of association test results in the MHC region. The -log10(P value) from a 
logistic regression of each SNP as well as HLA-B*35:02 on phenotype is plotted according to physical 
locations in the MHC region. Linkage disequilibrium between each of the SNPs and the lead GWAS SNP 
(rs146765245) is indicated by color. Associations with the GWAS SNPs were not genome-wide 
significant, but imputation of HLA types revealed a genome-wide significant association with HLA-
B*35:02. Local recombination rate in this region is also shown with the second Y-axis on the right. 
Several HLA genes with their direction of transcription are marked by arrows on the bottom and the 
locations of SNPs are marked by vertical bars on the top. This plot is generated using the web tool 
LocusZoom at http://locuszoom.sph.umich.edu/locuszoom/. 
Figure 3. Molecular docking of minocycline in the HLA-B*35:02 antigen binding cleft.  (a) A ribbon 
diagram of HLA-B*35:02 showing minocycline with white sticks for carbon, blue for nitrogen, red for 
oxygen, and white for hydrogen. Yellow dashes represent polar interactions between minocycline and 
HLA-B*35:02. (b). Minocycline is shown in the top scoring binding orientation predicted by molecular 
docking using AutoDock Vina. The molecular surface of HLA-B*35:02 is showing as violet for carbon, 
blue for nitrogen, red for oxygen, and white for hydrogen. 
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Table 1.  Presenting features and outcomes of 25 patients with minocycline hepatotoxicity 
 
Characteristic n Total Sample 
HLA-B*35:02 (-) 
N=21          
HLA B-35:02 (+) 
N=4 p-value 
Demographics 
  
   
Age, median 
(interquartile range) 25  
19  
(17.9-41.0) 
19.5  
(17.3-41.0) 
19.6 
(19.5-30.2) 
0.96 
% Female 25 80%  81%  75%  1 
BMI (mean +/- SD) 21 22.9 +/- 3.9 22.7 +/- 4.2 23.8 +/- 2.6 0.56 
Clinical Features 
Latency (days)   
(mean +/- SD) 24 346 +/- 268 387 +/- 249 416 +/- 376 0.69 
R-value at onset 
(mean +/- SD) 25 15.6 +/- 11.5 17.6 +/- 12.8 8.4 +/- 4.8 0.030 
ALT (U/L) at onset,          
median (25th, 75th) 22 1111(278, 1996) 1474 (278, 2009) 545 (343, 1169) 0.50 
Bilirubin (mg/dL) at 
onset, median (25th, 
75th) 
22 4.5 (0.5, 7.6) 4.9 (0.7, 7.7) 0.4 (0.3, 3.6) 0.05 
Immunoallergic features: 
     Fever 25 8/25 (32%) 7/21 (33%) 1/4 (25%) 1 
     Rash 25 5/25 (20%) 5/21 (24%) 0/4 (0%) 0.55 
     Eosinophilia 23 1/23 (4.3%) 1/19 (5.3%) 0/4 (0%) 1 
+ANA 21 19/21 (90%) 15/17 (88%) 4/4 (100%) 1 
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+SmAb 21 7/21 (33%) 6/17 (35%) 1/4 (25%) 1 
Received 
Corticosteroids 22 11/22 (50%) 9/18 (50%) 2/4 (50%) 1 
Chronic DILI 21 5/17 (24%) 3/17 (18%) 2/4 (50%) 0.23 
DILIN Severity Score, 
median (25th, 75th)  22 2.0 (1.0, 2.0) 2.0 (1.0, 2.0) 1.0 (1.0, 2.0) 0.36 
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Table 2-  Liver histopathology in 8 DILIN subjects with minocycline hepatotoxicity 
Age 
(years) 
Gender HLA-
B*35:02 
carrier 
Duration of 
Minocycline 
use (d) 
Days from 
DILI onset 
to biopsy 
Findings 
17 Male - 
570 144 
Marked chronic 
hepatitis, eosinophils 
18 Female  
- 
701 22 
Marked chronic 
hepatitis, plasma 
cells and eosinophils, 
bridging fibrosis 
16 Female  
- 197 101 
Moderate chronic 
hepatitis 
55 Female  
- 
588 8 
Moderate cholestatic 
chronic hepatitis, 
plasma cells, 
eosinophils 
17 Female  
- 
387 220 
Mild chronic 
hepatitis, plasma 
cells 
31 Female  
- 
43 10 
Marked acute 
cholestatic hepatitis, 
plasma cells, 
eosinophils 
19 Female  
+ 
74 5 
Marked acute 
hepatitis, plasma 
cells, early bridging 
fibrosis 
19 Male  
- 
384 2 
Marked acute 
cholestatic hepatitis, 
eosinophils 
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Table 3. Association test results for top imputed HLA allele and top GWAS SNP in MHC region  
 
MAF 
(cases) 
MAF 
(controls) 
 
Carrier 
Frequency 
(cases, N = 25) 
 
Carrier 
Frequency 
(controls, N= 
6,835) 
Odds Ratio 
 (95% CI) 
p-value 
HLA-B*35:02 8% 0.3% 16.0% 0.6% 
29.6  
(7.8, 89.8) 
2.57 x 10
-8 
rs146765245 10% 0.2% 16.0% 0.4% 
29.9  
(8.1, 97.6) 
1.01 x 10
-7 
 
MAF=  minor allele frequency 
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Example:   A ribbon diagram of HLA-B *35:02 demonstrating docking of a minocycline molecule in 
protein binding cleft. 
 
 
 
